139 related articles for article (PubMed ID: 11075943)
1. Case report of a novel amino acid deletion in codon 67 and T69G substitution in the reverse transcriptase of HIV-1.
Giri J; Rueda HJ; Monticelli A; Planes N
Antivir Ther; 2000 Sep; 5(3):227-8. PubMed ID: 11075943
[No Abstract] [Full Text] [Related]
2. Reverse transcriptase fidelity and HIV-1 variation.
Balzarini J; Pelemans H; De Clercq E; Karlsson A; Kleim JP
Science; 1997 Jan; 275(5297):229-30; author reply 230-1. PubMed ID: 8999551
[No Abstract] [Full Text] [Related]
3. Reverse transcriptase fidelity and HIV-1 variation.
Keulen W; Nijhuis M; Schuurman R; Berkhout B; Boucher C
Science; 1997 Jan; 275(5297):229; author reply 230-1. PubMed ID: 8999550
[No Abstract] [Full Text] [Related]
4. Current insights into reverse transcriptase inhibitor-associated resistance.
Wainberg MA; White AJ
Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
[No Abstract] [Full Text] [Related]
5. Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles.
Imamichi T; Murphy MA; Imamichi H; Lane HC
J Virol; 2001 Apr; 75(8):3988-92. PubMed ID: 11264389
[TBL] [Abstract][Full Text] [Related]
6. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.
Romano L; Venturi G; Bloor S; Harrigan R; Larder BA; Major JC; Zazzi M
J Infect Dis; 2002 Apr; 185(7):898-904. PubMed ID: 11920313
[TBL] [Abstract][Full Text] [Related]
7. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.
Winters MA; Merigan TC
Antimicrob Agents Chemother; 2005 Jul; 49(7):2575-82. PubMed ID: 15980322
[No Abstract] [Full Text] [Related]
8. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
Kagan RM; Merigan TC; Winters MA; Heseltine PN
Antivir Ther; 2004 Oct; 9(5):827-8. PubMed ID: 15535422
[No Abstract] [Full Text] [Related]
9. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
[TBL] [Abstract][Full Text] [Related]
10. The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.
Parkin NT; Gupta S; Chappey C; Petropoulos CJ
Antimicrob Agents Chemother; 2006 Jan; 50(1):351-4. PubMed ID: 16377709
[TBL] [Abstract][Full Text] [Related]
11. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.
Sato H; Tomita Y; Ebisawa K; Hachiya A; Shibamura K; Shiino T; Yang R; Tatsumi M; Gushi K; Umeyama H; Oka S; Takebe Y; Nagai Y
J Virol; 2001 Jun; 75(12):5604-13. PubMed ID: 11356968
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of drug resistance mutations in Spain among both naive and pretreated patients.
Soriano V
Antivir Ther; 1999; 4 Suppl 3():57-63. PubMed ID: 16021872
[TBL] [Abstract][Full Text] [Related]
14. Resistance to (-)-2',3'-dideoxy-3'-thiacytidine (3TC) in HIV-1 isolated from paediatric patients.
Wainberg MA; Lewis L; Salomon H; Gu Z; Keller A; Cammack N; Goldsmith J; Church J; Spira B; Wheeler S; Pizzo P
Antivir Ther; 1996 Apr; 1(2):98-104. PubMed ID: 11321185
[TBL] [Abstract][Full Text] [Related]
15. Primary lamivudine resistance in acute/early human immunodeficiency virus infection.
Conway B; Montessori V; Rouleau D; Montaner JS; O'Shaughnessy MV; Fransen S; Shillington A; Weislow O; Mayers DL
Clin Infect Dis; 1999 Apr; 28(4):910-1. PubMed ID: 10825060
[No Abstract] [Full Text] [Related]
16. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
[TBL] [Abstract][Full Text] [Related]
17. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
[TBL] [Abstract][Full Text] [Related]
18. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
19. Distinct patterns of natural selection in the reverse transcriptase gene of HIV-1 in the presence and absence of antiretroviral therapy.
de S Leal E; Holmes EC; Zanotto PM
Virology; 2004 Aug; 325(2):181-91. PubMed ID: 15246258
[TBL] [Abstract][Full Text] [Related]
20. High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1.
Imamichi T; Sinha T; Imamichi H; Zhang YM; Metcalf JA; Falloon J; Lane HC
J Virol; 2000 Jan; 74(2):1023-8. PubMed ID: 10623768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
